HK1187613A1 - 作為組胺 受體配體的化合物 - Google Patents
作為組胺 受體配體的化合物Info
- Publication number
- HK1187613A1 HK1187613A1 HK14100570.2A HK14100570A HK1187613A1 HK 1187613 A1 HK1187613 A1 HK 1187613A1 HK 14100570 A HK14100570 A HK 14100570A HK 1187613 A1 HK1187613 A1 HK 1187613A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- histamine
- compounds
- receptor ligands
- ligands
- receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN520CH2011 | 2011-02-23 | ||
PCT/IN2011/000380 WO2012114348A1 (en) | 2011-02-23 | 2011-06-07 | Novel compounds as histamine h3 receptor ligands |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1187613A1 true HK1187613A1 (zh) | 2014-04-11 |
Family
ID=54290090
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK14100570.2A HK1187613A1 (zh) | 2011-02-23 | 2014-01-20 | 作為組胺 受體配體的化合物 |
Country Status (28)
Country | Link |
---|---|
US (1) | US9079888B2 (zh) |
EP (1) | EP2694492B1 (zh) |
JP (1) | JP5805792B2 (zh) |
KR (1) | KR101554407B1 (zh) |
CN (1) | CN103443093B (zh) |
AP (1) | AP3340A (zh) |
AU (1) | AU2011360550B2 (zh) |
BR (1) | BR112013021496B1 (zh) |
CA (1) | CA2827567C (zh) |
CY (1) | CY1116721T1 (zh) |
DK (1) | DK2694492T3 (zh) |
EA (1) | EA023260B1 (zh) |
ES (1) | ES2548284T3 (zh) |
HK (1) | HK1187613A1 (zh) |
HR (1) | HRP20151003T1 (zh) |
HU (1) | HUE025163T2 (zh) |
IL (1) | IL228019A (zh) |
ME (1) | ME02212B (zh) |
MX (1) | MX339858B (zh) |
NZ (1) | NZ614567A (zh) |
PL (1) | PL2694492T3 (zh) |
PT (1) | PT2694492E (zh) |
RS (1) | RS54248B1 (zh) |
SG (1) | SG192858A1 (zh) |
SI (1) | SI2694492T1 (zh) |
SM (1) | SMT201500238B (zh) |
WO (1) | WO2012114348A1 (zh) |
ZA (1) | ZA201306328B (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUP1300139A2 (en) * | 2013-03-06 | 2014-09-29 | Richter Gedeon Nyrt | Phenoxypiperidine h3 antagonists |
HUE041465T2 (hu) | 2014-08-16 | 2019-05-28 | Suven Life Sciences Ltd | N-[4-(1-ciklobutil-piperidin-4-il-oxi)fenil]-2-(morfolin-4-il)-acetamid-dihidroklorid nagyüzemi gyártási folyamata |
WO2018033847A1 (en) * | 2016-08-18 | 2018-02-22 | Suven Life Sciences Limited | Combination of histamine-3 receptor inverse agonists with acetylcholinesterase inhibitors |
JP6734469B2 (ja) * | 2016-08-18 | 2020-08-05 | スヴェン・ライフ・サイエンシーズ・リミテッドSuven Life Sciences Limited | ヒスタミン−3受容体インバースアゴニスト、アセチルコリンエステラーゼ阻害剤及びnmda受容体アンタゴニストの3種組合せ |
MA52850A (fr) * | 2018-05-31 | 2021-04-21 | Suven Life Sciences Ltd | Méthode de traitement avec un agoniste inverse du récepteur de l'histamine-3 |
WO2022113008A1 (en) | 2020-11-27 | 2022-06-02 | Richter Gedeon Nyrt. | Histamine h3 receptor antagonists/inverse agonists for the treatment of autism spectrum disorder |
WO2023166349A2 (zh) * | 2022-03-02 | 2023-09-07 | 杭州百诚医药科技股份有限公司 | 苯基脲类衍生物及其医药用途 |
CN116693470A (zh) * | 2022-03-02 | 2023-09-05 | 杭州百诚医药科技股份有限公司 | 组胺h3受体抑制剂及其医药用途 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9725541D0 (en) * | 1997-12-02 | 1998-02-04 | Pharmacia & Upjohn Spa | Amino-benzothiazole derivatives |
CA2419036A1 (en) * | 2000-08-08 | 2002-02-14 | Ortho-Mcneil Pharmaceutical, Inc. | Non-imidazole aryloxypiperidines as h3 receptor ligands |
CA2441080A1 (en) * | 2001-03-23 | 2002-10-03 | Eli Lilly And Company | Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses |
ATE441417T1 (de) * | 2002-12-20 | 2009-09-15 | Glaxo Group Ltd | Benzoädüazepinderivate für die behandlung von neurologischen krankheiten |
PL1735278T3 (pl) * | 2004-04-01 | 2010-06-30 | Lilly Co Eli | Związki receptora histaminowego H3, wytwarzanie i zastosowania terapeutyczne |
US8008301B2 (en) | 2004-04-01 | 2011-08-30 | Eli Lilly And Company | Histamine H3 receptor agents, preparation and therapeutic uses |
JP4942654B2 (ja) | 2004-08-23 | 2012-05-30 | イーライ リリー アンド カンパニー | ヒスタミンh3受容体薬剤、製剤及び治療的使用 |
CL2008002622A1 (es) | 2007-09-06 | 2009-11-27 | Glaxo Group Ltd | 1-(1-metiletil)-4-{[4-(tetrahidro-2h-piran-4-iloxi)fenil]carbonil}piperazina y su sal hidrocloruro; formas cristalinas de la sal; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento o profilaxis de deterioro cognitivo, fatiga o trastorno del sueno. |
DK2215058T3 (da) * | 2007-10-17 | 2012-03-12 | Sanofi Sa | Substituerede N-phenylbipyrrolidinureaer og terapeutisk anvendelse deraf |
US7799816B2 (en) | 2008-02-04 | 2010-09-21 | Roche Palo Alto Llc | Imidazolinylmethyl aryl sulfonamide |
CN102046624A (zh) | 2008-03-31 | 2011-05-04 | 埃沃特克股份有限公司 | 作为组胺h3受体拮抗剂的四氢萘啶及其氮杂衍生物 |
JP5780954B2 (ja) | 2008-05-08 | 2015-09-16 | エヴォテック・アクチエンゲゼルシャフト | ヒスタミンh3受容体アンタゴニストとしてのアゼチジン類及びシクロブタン類 |
EP2350048A2 (en) | 2008-10-16 | 2011-08-03 | Schering Corporation | Azine derivatives and methods of use thereof |
-
2011
- 2011-06-07 SI SI201130601T patent/SI2694492T1/sl unknown
- 2011-06-07 AU AU2011360550A patent/AU2011360550B2/en active Active
- 2011-06-07 MX MX2013009683A patent/MX339858B/es active IP Right Grant
- 2011-06-07 WO PCT/IN2011/000380 patent/WO2012114348A1/en active Application Filing
- 2011-06-07 KR KR1020137024919A patent/KR101554407B1/ko active IP Right Grant
- 2011-06-07 RS RS20150610A patent/RS54248B1/en unknown
- 2011-06-07 EA EA201391211A patent/EA023260B1/ru unknown
- 2011-06-07 DK DK11749555.6T patent/DK2694492T3/en active
- 2011-06-07 EP EP11749555.6A patent/EP2694492B1/en active Active
- 2011-06-07 BR BR112013021496-1A patent/BR112013021496B1/pt active IP Right Grant
- 2011-06-07 PL PL11749555T patent/PL2694492T3/pl unknown
- 2011-06-07 JP JP2013554978A patent/JP5805792B2/ja active Active
- 2011-06-07 NZ NZ61456711A patent/NZ614567A/en unknown
- 2011-06-07 US US14/000,362 patent/US9079888B2/en active Active
- 2011-06-07 AP AP2013007088A patent/AP3340A/xx active
- 2011-06-07 ME MEP-2015-151A patent/ME02212B/me unknown
- 2011-06-07 CN CN201180069505.8A patent/CN103443093B/zh active Active
- 2011-06-07 CA CA2827567A patent/CA2827567C/en active Active
- 2011-06-07 ES ES11749555.6T patent/ES2548284T3/es active Active
- 2011-06-07 PT PT117495556T patent/PT2694492E/pt unknown
- 2011-06-07 HU HUE11749555A patent/HUE025163T2/en unknown
- 2011-06-07 SG SG2013063060A patent/SG192858A1/en unknown
-
2013
- 2013-08-18 IL IL228019A patent/IL228019A/en active IP Right Grant
- 2013-08-22 ZA ZA2013/06328A patent/ZA201306328B/en unknown
-
2014
- 2014-01-20 HK HK14100570.2A patent/HK1187613A1/zh unknown
-
2015
- 2015-09-23 HR HRP20151003TT patent/HRP20151003T1/hr unknown
- 2015-09-28 CY CY20151100859T patent/CY1116721T1/el unknown
- 2015-10-02 SM SM201500238T patent/SMT201500238B/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL286152A (en) | Modified imidazopyridinyl-aminopyridine compounds | |
GB201106395D0 (en) | Compounds | |
GB201107197D0 (en) | Compounds | |
HK1187613A1 (zh) | 作為組胺 受體配體的化合物 | |
AP3307A (en) | Heteroaryl compounds as 5-HT4 receptor ligands | |
HK1180955A1 (zh) | 作為組胺 受體配體的雜環基化合物 | |
HK1204620A1 (zh) | 作爲組胺 受體配體的丙烯醯胺化合物 | |
GB201105659D0 (en) | Compounds | |
HUP1100731A2 (en) | Complex forming compounds | |
ZA201409244B (en) | Acrylamide compounds as histamine h3 receptor ligands | |
GB201107204D0 (en) | Compounds | |
GB201106262D0 (en) | Compounds | |
GB201106178D0 (en) | Compounds | |
GB201105511D0 (en) | Compounds | |
GB201105531D0 (en) | Compounds |